Literature DB >> 511928

Heparin dose for accurate anticoagulation in cardiac surgery.

D B Doty, H W Knott, J L Hoyt, J A Koepke.   

Abstract

A simplified technique relating individual heparin dose to desired anticoagulant effect was used in 152 patients during cardiac surgery. Activated clotting time (act) was measured by semi-automated technique (Hemochron) before and after heparin, 200 U/kg I.V. Two point linear dose-response curve allowed calculation of any additional heparin required for uniform ACT of 480 seconds. Mean heparin requirement was 330 U/kg) (range 200--600 U/kg) mean requirements for adults (mean = 310 U/kg) were significantly less (p less than 0.001) than for children (mean = 430 U/kg). Individual dose-response curves suggested 20 patients (13%) could have been below adequate anticoagulant levels (ACT less than 300 seconds) using our previous formula for heparin dosage (9000 U/m2). At completion of cardiopulmonary bypass, measurement of ACT provided circulating heparin level from the dose-response curve. Protamine dose (1.3 mg/100 U. heparin) was individualized to precisely reverse anticoagulant effect to control ACT in 127 of 152 patients (84%) with a single dose. Elimination of patient and product variability by simplified semi-automated dose-response technique for heparin therapy provides uniform anticoagulant effect and its accurate neutralization. This technique is recommended for precise anticoagulant therapy during open heart surgery.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511928

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  4 in total

Review 1.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

2.  Bioengineering murine mastocytoma cells to produce anticoagulant heparin.

Authors:  Leyla Gasimli; Charles A Glass; Payel Datta; Bo Yang; Guoyun Li; Trent R Gemmill; Jong Youn Baik; Susan T Sharfstein; Jeffrey D Esko; Robert J Linhardt
Journal:  Glycobiology       Date:  2013-12-09       Impact factor: 4.313

3.  Time-related effects of heparin sulfate on regional and systemic anticoagulation.

Authors:  C K Vincent; T W Wakefield; B Lindblad; J C Stanley; A W Fleming
Journal:  J Natl Med Assoc       Date:  1992-11       Impact factor: 1.798

4.  Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs.

Authors:  Kirill Kondratov; Dmitry Kurapeev; Maxim Popov; Marina Sidorova; Sarkis Minasian; Michael Galagudza; Anna Kostareva; Anton Fedorov
Journal:  Biomol Detect Quantif       Date:  2016-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.